ScripBiohaven’s stock price closed down 15.2% at $19.84 on 25 April on the news that the company withdrew its application for European Medicines Agency approval of troriluzole in the treatment of spinocere
ScripRezolute, Inc. believes it has a viable oral drug for diabetic eye disease that warrants development in late-stage clinical studies. RZ402, an oral plasma kallikrein inhibitor (PKI), could represent
Pink SheetNTLA-2002 and 4D-150, which are single-dose, gene therapy candidates for hereditary angioedema and neovascular age-related macular degeneration (wet AMD) respectively, are among the latest products to
Pink SheetGSK’s Walmsley: No Change To M&A Post FTC-Amgen/Horizon GSK plc plans no shift in its dealmaking strategy following the US Federal Trade Commission’s attempt to block Amgen, Inc. ’s $27.8bn acquisi